Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Trial ID or NCT#
NCT00466921
Status
NOT RECRUITING
Purpose
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.
Official Title
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Eligibility Criteria
Ages Eligible for Study: 18 Years to 120 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Youn H Kim
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Contact us to find out if this trial is right for you.
Contact
Natalie Viakhireva
6507238949
View on ClinicalTrials.gov
